Nexalin Technology, Inc. Common Stock
NXL US65345B2016
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Annual Performance 1
| 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|
| -67% | -49% | 590% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Shelton Carolyn Hamby VP |
2.20 USD |
6,000 Bought |
13,200 USD |
12/03/2025 | 12/03/2025 |
| Owens David CMO |
3.10 USD |
1,000 Bought |
3,100 USD |
04/02/2025 | 04/02/2025 |
| Owens David CMO |
2.98 USD |
1,000 Bought |
2,980 USD |
04/02/2025 | 04/02/2025 |
| Owens David CMO |
2.70 USD |
1,500 Bought |
4,050 USD |
28/01/2025 | 28/01/2025 |
| Owens David CMO |
2.70 USD |
1,000 Bought |
2,700 USD |
13/01/2025 | 23/01/2025 |
| Owens David CMO |
2.50 USD |
2,000 Bought |
5,000 USD |
13/01/2025 | 13/01/2025 |
| Owens David CMO |
2.19 USD |
500 Bought |
1,095 USD |
28/10/2024 | 28/10/2024 |
| Owens David CMO |
0.95 USD |
1,000 Bought |
950 USD |
13/08/2024 | 13/08/2024 |
| Owens David CMO |
1.75 USD |
1,000 Bought |
1,750 USD |
28/06/2024 | 28/06/2024 |
| Owens David CMO |
0.71 USD |
1,619 Bought |
1,149 USD |
18/06/2024 | 18/06/2024 |